Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 known ✓ | P08238 | 1/20 | 0.39 |
| ▸ | CCR5 known ✓ | P51681 | 2/20 | 0.35 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.30 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 2/20 | 0.35 |
| ▸ | CCR8 | P51685 | 2/20 | 0.35 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29861810 | 1.00 | NOS3 (0.45) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL30164264 | 0.98 | NOS3 (0.46) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL286660 | 0.98 | NOS3 (0.46) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL29505659 | 0.78 | NOS3 (0.50) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL18765135 | 0.78 | NOS3 (0.50) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL6445926 | 0.78 | NOS3 (0.50) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL873234 | 0.77 | NOS3 (0.48) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL29384905 | 0.77 | NOS3 (0.48) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL16039165 | 0.77 | CCR1 (0.34) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL2112705 | 0.77 | S1PR1 (0.39) | AGBL2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115089559-B | Preparation method of microsphere for injection | 山东济坤生物制药有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-115089559-A | Preparation method of microspheres for injection | 山东济坤生物制药有限公司 | 2022-09-23 | — | — | CN | claimed |
| EP-0240158-B1 | BENZIMIDAZOLE DERIVATIVES | TOKYO TANABE COMPANY LIMITED (JP) | 1991-04-03 | — | — | EP | claimed |
| EP-0240158-A1 | Benzimidazole derivatives | TOKYO TANABE COMPANY LIMITED (JP) | 1987-10-07 | — | — | EP | claimed |
| CN-115089559-B | Preparation method of microsphere for injection | 山东济坤生物制药有限公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-115089559-A | Preparation method of microspheres for injection | 山东济坤生物制药有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | AUTOIMMUNE PHARMA LLC (US) | 2020-05-14 | — | — | US | disclosed |
| CN-107915736-A | Adjacent nitro aroylation derivatives quasi-compound, preparation method and applications | 兰州大学 | 2018-04-17 | — | — | CN | disclosed |
| CN-104402867-A | Preparation method of esomeprazole impurities H and B | YANTAI VALIANT FINE CHEMICALS CO LTD | 2015-03-11 | — | — | CN | disclosed |
| US-8841295-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-09-23 | — | — | US | disclosed |
| CN-101541811-B | Pyrazolopyrimidine Derivatives | DAIICHI SANKYO CO LTD | 2014-07-09 | — | — | CN | disclosed |
| US-8710081-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| EP-0214479-A2 | Benzimidazol-2-ylpyridinium compounds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-03-18 | — | — | EP | disclosed |
| EP-0146370-A2 | Imidazoquinolines containing other heterocyclic groups | JOHN WYETH & BROTHER LIMITED (GB) | 1985-06-26 | — | — | EP | disclosed |
| US-4508905-A | GASTRIC ACID SECRETION INHIBITORS | AKTIEBOLAGET HASSLE (SE) | 1985-04-02 | — | — | US | disclosed |
| US-4359465-A | HETEROCYCLIC ALKYLSULFINYL BENZIMIDAZOLES | THE UPJOHN COMPANY (US) | 1982-11-16 | — | — | US | disclosed |
| US-4337257-A | Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion | AKTIEBOLAGET HASSLE (SE) | 1982-06-29 | — | — | US | disclosed |
| EP-0005129-B1 | SUBSTITUTED PYRIDYLSULFINYLBENZIMIDAZOLES HAVING GASTRIC ACID SECRETION PROPERTIES, PHARMACEUTICAL PREPARATIONS CONTAINING SAME, AND INTERMEDIATES FOR THEIR PREPARATION | Aktiebolaget Hässle (SE) | 1981-04-29 | — | — | EP | disclosed |
| US-4255431-A | Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion | AKTIEBOLAGET HASSLE (SE) | 1981-03-10 | — | — | US | disclosed |
| EP-0005129-A1 | Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties, pharmaceutical preparations containing same, and intermediates for their preparation | Aktiebolaget Hässle (SE) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | LTB4R, LTC4S, LTB4R2 | HSP90AA1 3433/4885HSP90AB1 3107/4885CCR5 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.